Literature DB >> 24752272

Activity of potent and selective host defense peptide mimetics in mouse models of oral candidiasis.

Lisa K Ryan1, Katie B Freeman2, Jorge A Masso-Silva3, Klaudia Falkovsky3, Ashwag Aloyouny3, Kenneth Markowitz3, Amy G Hise4, Mahnaz Fatahzadeh5, Richard W Scott2, Gill Diamond6.   

Abstract

There is a strong need for new broadly active antifungal agents for the treatment of oral candidiasis that not only are active against many species of Candida, including drug-resistant strains, but also evade microbial countermeasures which may lead to resistance. Host defense peptides (HDPs) can provide a foundation for the development of such agents. Toward this end, we have developed fully synthetic, small-molecule, nonpeptide mimetics of the HDPs that improve safety and other pharmaceutical properties. Here we describe the identification of several HDP mimetics that are broadly active against C. albicans and other species of Candida, rapidly fungicidal, and active against yeast and hyphal cultures and that exhibit low cytotoxicity for mammalian cells. Importantly, specificity for Candida over commensal bacteria was also evident, thereby minimizing potential damage to the endogenous microbiome which otherwise could favor fungal overgrowth. Three compounds were tested as topical agents in two different mouse models of oral candidiasis and were found to be highly active. Following single-dose administrations, total Candida burdens in tongues of infected animals were reduced up to three logs. These studies highlight the potential of HDP mimetics as a new tool in the antifungal arsenal for the treatment of oral candidiasis.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24752272      PMCID: PMC4068575          DOI: 10.1128/AAC.02649-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

1.  Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  T J Walsh; C E Gonzalez; S Piscitelli; J D Bacher; J Peter; R Torres; D Shetti; V Katsov; K Kligys; C A Lyman
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  The pharmacophore of short cationic antibacterial peptides.

Authors:  Morten B Strøm; Bengt Erik Haug; Merete L Skar; Wenche Stensen; Trine Stiberg; John S Svendsen
Journal:  J Med Chem       Date:  2003-04-24       Impact factor: 7.446

3.  Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; M A Pfaller; B Bustamante; E Canton; A Fothergill; J Fuller; G M Gonzalez; C Lass-Flörl; S R Lockhart; E Martin-Mazuelos; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M W Szeszs; G St-Germain; L X Bonfietti; J Guarro; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

Review 4.  Experimental oral candidiasis in animal models.

Authors:  Y H Samaranayake; L P Samaranayake
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

5.  beta-Defensin 1 contributes to pulmonary innate immunity in mice.

Authors:  Christian Moser; Daniel J Weiner; Elena Lysenko; Robert Bals; Jeffrey N Weiser; James M Wilson
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

6.  Oral lactoferrin treatment of experimental oral candidiasis in mice.

Authors:  Natsuko Takakura; Hiroyuki Wakabayashi; Hiroko Ishibashi; Susumu Teraguchi; Yoshitaka Tamura; Hideyo Yamaguchi; Shigeru Abe
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

7.  Uses and limitations of the XTT assay in studies of Candida growth and metabolism.

Authors:  D M Kuhn; M Balkis; J Chandra; P K Mukherjee; M A Ghannoum
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

8.  Clinical and histological findings of denture stomatitis as related to intraoral colonization patterns of Candida albicans, salivary flow, and dry mouth.

Authors:  Sandra Altarawneh; Sompop Bencharit; Luisito Mendoza; Alice Curran; David Barrow; Silvana Barros; John Preisser; Zvi G Loewy; Linda Gendreau; Steven Offenbacher
Journal:  J Prosthodont       Date:  2012-10-25       Impact factor: 2.752

Review 9.  Oral candidiasis.

Authors:  A Akpan; R Morgan
Journal:  Postgrad Med J       Date:  2002-08       Impact factor: 2.401

Review 10.  Recent mouse and rat methods for the study of experimental oral candidiasis.

Authors:  Anna C B P Costa; Cristiane A Pereira; Juliana C Junqueira; Antonio O C Jorge
Journal:  Virulence       Date:  2013-05-28       Impact factor: 5.882

View more
  15 in total

1.  β-Defensin 1 plays a role in acute mucosal defense against Candida albicans.

Authors:  Jeffrey Tomalka; Elaheh Azodi; Hema P Narra; Krupen Patel; Samantha O'Neill; Cisley Cardwell; Brian A Hall; James M Wilson; Amy G Hise
Journal:  J Immunol       Date:  2015-01-16       Impact factor: 5.422

Review 2.  Antimicrobial Peptide Mimics for Clinical Use: Does Size Matter?

Authors:  Johan Svenson; Natalia Molchanova; Christina I Schroeder
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

3.  LL-37 disrupts the Kaposi's sarcoma-associated herpesvirus envelope and inhibits infection in oral epithelial cells.

Authors:  David C Brice; Zsolt Toth; Gill Diamond
Journal:  Antiviral Res       Date:  2018-08-02       Impact factor: 5.970

4.  Antifungal Potential of Host Defense Peptide Mimetics in a Mouse Model of Disseminated Candidiasis.

Authors:  Mobaswar Hossain Chowdhury; Lisa Kathleen Ryan; Kartikeya Cherabuddi; Katie B Freeman; Damian G Weaver; Jeffry C Pelletier; Richard W Scott; Gill Diamond
Journal:  J Fungi (Basel)       Date:  2018-02-27

5.  Antibiofilm peptides against oral biofilms.

Authors:  Zhejun Wang; Ya Shen; Markus Haapasalo
Journal:  J Oral Microbiol       Date:  2017-06-14       Impact factor: 5.474

6.  Potent in vitro and in vivo antifungal activity of a small molecule host defense peptide mimic through a membrane-active mechanism.

Authors:  Lorenzo P Menzel; Hossain Mobaswar Chowdhury; Jorge Adrian Masso-Silva; William Ruddick; Klaudia Falkovsky; Rafael Vorona; Andrew Malsbary; Kartikeya Cherabuddi; Lisa K Ryan; Kristina M DiFranco; David C Brice; Michael J Costanzo; Damian Weaver; Katie B Freeman; Richard W Scott; Gill Diamond
Journal:  Sci Rep       Date:  2017-06-28       Impact factor: 4.379

Review 7.  Insights into the antimicrobial properties of hepcidins: advantages and drawbacks as potential therapeutic agents.

Authors:  Lisa Lombardi; Giuseppantonio Maisetta; Giovanna Batoni; Arianna Tavanti
Journal:  Molecules       Date:  2015-04-10       Impact factor: 4.411

Review 8.  Antiviral Activities of Human Host Defense Peptides.

Authors:  David C Brice; Gill Diamond
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

9.  Murepavadin, a Small Molecule Host Defense Peptide Mimetic, Activates Mast Cells via MRGPRX2 and MrgprB2.

Authors:  Aetas Amponnawarat; Chalatip Chompunud Na Ayudhya; Hydar Ali
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

10.  Preventive effects of the novel antimicrobial peptide Nal-P-113 in a rat Periodontitis model by limiting the growth of Porphyromonas gingivalis and modulating IL-1β and TNF-α production.

Authors:  Hong-Yan Wang; Li Lin; Wei Fu; Hui-Yuan Yu; Ning Yu; Li-Si Tan; Jya-Wei Cheng; Ya-Ping Pan
Journal:  BMC Complement Altern Med       Date:  2017-08-29       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.